Articles by Sarah Houlton - Pharmaceutical Executive

ADVERTISEMENT

Articles by Sarah Houlton

Some Alzheimer's Patients Left Behind

Eisai and Pfizer lose case against NICE to supply drugs to those with early-stage Alzheimer's disease
Oct 1, 2007

A landmark court case in the United Kingdom has left Alzheimer's patients with mild to moderate disease unable to receive any of the three drugs that might help them—Aricept (donepezil), Reminyl (galantamine), and Exelon (rivastigmine). Eisai and Pfizer, which make and market Aricept, had challenged the ruling made last year by the National Institute for Clinical Excellence that the drugs should be prescribed only to patients in the later stages of the disease. They were granted a judicial review—the first time one of NICE's decisions had been challenged in this way—and while the judge upheld one part of the challenge, the other two parts were dismissed and NICE's guidance stands.

Incentives Incense Industry in UK

The British pharma organization challenges the government's call for specific statin switches
Sep 1, 2007

The Association of the British Pharmaceutical Industry is challenging the UK government over the financial incentives being offered by the Department of Health (DH) to encourage doctors to switch patients from on-patent medicines to specific generic alternatives. ABPI believes the way the incentives are structured contravenes EU law—if pharma companies were to offer similar payments, they would be in serious trouble.

Make Resistance Futile

Patients are losing the battle against bacteria. Can pharma be convinced to swing the sword of new antibiotic development?
Jul 30, 2007

Scare stories about antibiotic-resistant bacteria are all too common in the mass media these days. In the United Kingdom alone, the number of deaths from methicillin-resistant Staphylococcus aureus almost doubled between 2001 and 2005 to more than 2,000. The situation with Clostridium difficile is even worse, with UK deaths tripling to almost 4,000 over the same period. The big problem is that the incidence is growing, yet few antibiotics are being developed that will be able to kill the resistant bacteria.

Money-Back Guarantee

Jul 25, 2007

UK pharma company offers to pick up the tab

Contamination Alert

Jul 25, 2007

Tainted batches of Viracept pulled from European shelves.

Five-Year Survivor: European Edition

There seems to be no race for the cure in the United Kingdom. Will cancer networks fill the gap?
Jul 3, 2007

Says Roche UK CEO John Melville: "There is little difference in the incidence of cancer, in broad terms, across Europe, but cancer survival is very different"

Global Report: Single-Source Supply

Pfizer's move to consolidate its drug supply chain in the United Kingdom may signal safer—but more expensive—drugs
Jun 1, 2007

Stakeholders worry that less competition among drug suppliers in the United Kingdom could mean higher prices and a bigger bill for the National Health Service

Global Report: Pure and Simple

Will the EC's upcoming drug-safety plan be just what the doctor ordered or end up an indecent proposal?
May 1, 2007

It's not always obvious just who is reponsible for the various steps of pharmacovigilance.

Global Report: If It Ain't Broke

Under the UK's pricing scheme, drug prices have dropped by 21 percent in 10 years. Is it really time for a change?
Apr 1, 2007

If the uk's office of fair trading (OFT) is to be believed, Brits are overpaying for their medicines to the tune of ?500 million a year. That's the conclusion the OFT came to in its long-awaited report on the Pharmaceutical Pricing Regulation Scheme (PPRS), the arcane method by which drug prices are set in the United Kingdom.

ADVERTISEMENT

Click here